Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5842555 | 0.91 | NPSR1 (0.61) | ALDH1A1MAPTUSP2GAANPSR1 | |
| SCHEMBL5843649 | 0.91 | ALDH1A1 (0.60) | ALDH1A1MAPTUSP2GAANPSR1 | |
| SCHEMBL5843916 | 0.90 | ALDH1A1 (0.71) | ALDH1A1MAPTGAAPOLBKMT2A | |
| SCHEMBL5843005 | 0.87 | ALDH1A1 (0.49) | ALDH1A1MAPTUSP2GAANPSR1 | |
| SCHEMBL5844447 | 0.87 | ALDH1A1 (0.61) | ALDH1A1USP2GAAPOLBKMT2A | |
| SCHEMBL5842345 | 0.85 | NPSR1 (0.64) | ALDH1A1MAPTUSP2GAANPSR1 | |
| SCHEMBL5842512 | 0.82 | ALDH1A1 (0.62) | ALDH1A1MAPTUSP2GAANPSR1 | |
| SCHEMBL5842567 | 0.82 | MAPT (0.60) | ALDH1A1MAPTUSP2GAANPSR1 | |
| SCHEMBL5842831 | 0.82 | MAPT (0.65) | ALDH1A1MAPTUSP2GAANPSR1 | |
| SCHEMBL5841214 | 0.81 | MAPT (0.58) | ALDH1A1MAPTUSP2GAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192292-A1 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2005-09-01 | — | — | US | claimed |
| US-7067549-B2 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2006-06-27 | — | — | US | disclosed |
| US-20050192292-A1 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192292-A1 | Pyrrolidone carboxamides | NPY1R, NPY5R, NPY2R | ALDH1A1 3034/4885MAPT 4395/4885USP2 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.